John Paul Murad

Combining 177Lu-PSMA-617 radioligand therapy with PSCA-CAR T cells improves tumor control and survival in prostate cancer models by overcoming antigen heterogeneity and reshaping the immunosuppressive tumor microenvironment.

This study combines focal radiotherapy, cyclophosphamide, and PSCA-CAR T cells to enhance antitumor responses and survival in prostate cancer models.

This study develops and tests IL12-engineered human PSMA-CAR T cells for advanced prostate cancer, showing improved anti-tumor activity and safety.

This study engineers CAR T cells with PDL1-IL12 fusion proteins to enhance anti-tumor responses in solid tumors by improving T cell function and reducing systemic inflammation.